Avillion has appointed Dr Anders Gersel Pedersen as its new non-executive director of Bond 2 Development 2 GP.

Dr Pedersen is currently a board member of Genmab A/S, deputy chairman of Bavarian Nordic A/S, and board member of Hansa Medical AB. He has a wealth of business and management experience in the pharmaceutical industry, including expertise in clinical research, development, regulatory affairs and product life cycle management. He is also the former executive vice president of research & development of H. Lundbeck A/S.

Avillion LLP’s chief executive officer, Dr Allison Jeynes commented on the appointment: “Anders has an impressive track record in developing new medicines demonstrated by his distinguished career in research and development within the pharmaceutical industry. I am delighted that Avillion is now set to benefit from this experience as we continue to deliver on the clinical programmes we are running and to assess new opportunities.”